187 related articles for article (PubMed ID: 23872196)
21. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
[TBL] [Abstract][Full Text] [Related]
22. Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations.
Jones RL; Wise H; Clark R; Whiting RL; Bley KR
Br J Pharmacol; 2006 Sep; 149(1):110-20. PubMed ID: 16880763
[TBL] [Abstract][Full Text] [Related]
23. Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery.
Jones RL; Qian YM; Wise H; Wong HN; Lam WL; Chan HW; Yim AP; Ho JK
J Cardiovasc Pharmacol; 1997 Apr; 29(4):525-35. PubMed ID: 9156364
[TBL] [Abstract][Full Text] [Related]
24. Sustained Neurological Recovery After Stroke in Aged Rats Treated With a Novel Prostacyclin Analog.
Yang C; DeMars KM; Alexander JC; Febo M; Candelario-Jalil E
Stroke; 2017 Jul; 48(7):1948-1956. PubMed ID: 28588054
[TBL] [Abstract][Full Text] [Related]
25. Distinction between relaxations induced via prostanoid EP(4) and IP(1) receptors in pig and rabbit blood vessels.
Jones RL; Chan K
Br J Pharmacol; 2001 Sep; 134(2):313-24. PubMed ID: 11564649
[TBL] [Abstract][Full Text] [Related]
26. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
27. Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Asaki T; Kuwano K; Morrison K; Gatfield J; Hamamoto T; Clozel M
J Med Chem; 2015 Sep; 58(18):7128-37. PubMed ID: 26291199
[TBL] [Abstract][Full Text] [Related]
28. Different efficacy of inhaled and oral medications in pulmonary hypertension.
AbuHalimeh BJ; Parambil JG; Tonelli AR
Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
[TBL] [Abstract][Full Text] [Related]
29. Prostacyclin release and receptor activation: differential control of human pulmonary venous and arterial tone.
Norel X; Walch L; Gascard JP; deMontpreville V; Brink C
Br J Pharmacol; 2004 Jun; 142(4):788-96. PubMed ID: 15172959
[TBL] [Abstract][Full Text] [Related]
30. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension.
Falcetti E; Hall SM; Phillips PG; Patel J; Morrell NW; Haworth SG; Clapp LH
Am J Respir Crit Care Med; 2010 Nov; 182(9):1161-70. PubMed ID: 20622039
[TBL] [Abstract][Full Text] [Related]
31. Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon.
Rudd JA; Qian Ym; Tsui KK; Jones RL
Br J Pharmacol; 2000 Feb; 129(4):782-90. PubMed ID: 10683203
[TBL] [Abstract][Full Text] [Related]
32. Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblasts.
Corboz MR; Salvail W; Gagnon S; LaSala D; Laurent CE; Salvail D; Chen KJ; Cipolla D; Perkins WR; Chapman RW
Prostaglandins Other Lipid Mediat; 2021 Feb; 152():106486. PubMed ID: 33011365
[TBL] [Abstract][Full Text] [Related]
33. Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn.
Lakshminrusimha S; Porta NF; Farrow KN; Chen B; Gugino SF; Kumar VH; Russell JA; Steinhorn RH
Pediatr Crit Care Med; 2009 Jan; 10(1):106-12. PubMed ID: 19057444
[TBL] [Abstract][Full Text] [Related]
34. Assessing the agonist profiles of the prostacyclin analogues treprostinil and naxaprostene, particularly their DP₁ activity.
Syed NI; Jones RL
Prostaglandins Leukot Essent Fatty Acids; 2015 Apr; 95():19-29. PubMed ID: 25542069
[TBL] [Abstract][Full Text] [Related]
35. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug.
Kuwano K; Hashino A; Asaki T; Hamamoto T; Yamada T; Okubo K; Kuwabara K
J Pharmacol Exp Ther; 2007 Sep; 322(3):1181-8. PubMed ID: 17545310
[TBL] [Abstract][Full Text] [Related]
36. Partial agonism of taprostene at prostanoid IP receptors in vascular preparations from guinea-pig, rat, and mouse.
Chan KM; Jones RL
J Cardiovasc Pharmacol; 2004 Jun; 43(6):795-807. PubMed ID: 15167273
[TBL] [Abstract][Full Text] [Related]
37. Raloxifene relaxes rat pulmonary arteries and veins: roles of gender, endothelium, and antagonism of Ca2+ influx.
Chan YC; Leung FP; Yao X; Lau CW; Vanhoutte PM; Huang Y
J Pharmacol Exp Ther; 2005 Mar; 312(3):1266-71. PubMed ID: 15550571
[TBL] [Abstract][Full Text] [Related]
38. Cross-species comparison of the metabolism and excretion of selexipag.
Ichikawa T; Yamada T; Treiber A; Gnerre C; Segrestaa J; Seeland S; Nonaka K
Xenobiotica; 2019 Mar; 49(3):284-301. PubMed ID: 29468921
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi
Kuwano K; Kosugi K; Fuchikami C; Funaki S
Nihon Yakurigaku Zasshi; 2021; 156(3):178-186. PubMed ID: 33952848
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptor-β/δ, the acute signaling factor in prostacyclin-induced pulmonary vasodilation.
Li Y; Connolly M; Nagaraj C; Tang B; Bálint Z; Popper H; Smolle-Juettner FM; Lindenmann J; Kwapiszewska G; Aaronson PI; Wohlkoenig C; Leithner K; Olschewski H; Olschewski A
Am J Respir Cell Mol Biol; 2012 Mar; 46(3):372-9. PubMed ID: 22021335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
